Cangfu Daotan decoction with Diane-35 in phlegm-dampness polycystic ovary syndrome: a meta-analysis and systematic review
Abstract
Background: To systematically evaluate the efficacy of Cangfu Daotan decoction combined with Diane-35 in treating phlegm-dampness polycystic ovary syndrome (PCOS) and its effects on endocrine- and metabolism-related outcomes.
Methods: Major English and Chinese databases (PubMed, Embase, Cochrane Library, Web of Science, CNKI, Wanfang, CQVIP, and SinoMed) were searched. Randomized controlled trials comparing Cangfu Daotan-based therapy plus Diane-35 versus Diane-35-based regimens were included. Two reviewers independently screened studies, extracted data, and assessed the risk of bias via the Cochrane tool. The meta-analysis was conducted with RevMan 5.4. The relative risk (RR) with 95% confidence intervals (CIs) was used for dichotomous outcomes, and the mean difference (MD) with 95% CIs was used for continuous outcomes. Fixed- or random-effects models were applied according to heterogeneity (I 2 threshold of 50%). Publication bias was assessed via funnel plots.
Results: Sixteen trials were included. Compared with the controls, the combination therapy significantly improved the total effective rate (RR = 1.24, 95% CI 1.18-1.31, p p p = 0.01), and the LH/FSH ratio (MD = -0.27, 95% CI -0.43 to -0.12, p = 0.0006). BMI also decreased (MD = -1.55, 95% CI -3.06 to -0.04, p = 0.04). Funnel plots suggested no obvious publication bias. Overall risk-of-bias assessment indicated insufficient reporting or implementation of blinding and unclear allocation concealment.
Conclusion: Cangfu…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.